Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
Official source
EMBLAVEO (aztreonam and avibactam) for injection
Product / population
Adults; IV fixed combination; doses below are TOTAL combination grams.
Renal measure
Not specified; verify before use
Source revision
Retrieved
2026-09-05 (not the revision date)
Renal-adjusted loading and maintenance doses
Use Cockcroft-Gault CrCl in mL/min. All infusions last 3 hours.
>50: load 2.67 g, then 2 g every 6 hours.
>30 to 50: load 2.67 g, then 1 g every 6 hours.
>15 to 30: load 1.8 g, then 0.9 g every 8 hours.
<=15, including HD: load 1.33 g, then 0.9 g every 12 hours.
Timing and limits
Maintenance starts at the next dosing interval after the single load; intervals run from infusion start to infusion start. Give after HD on dialysis days and monitor changing renal function closely. The labeled course is 5-14 days with concurrent metronidazole. Approval rests on limited clinical safety/efficacy data.
Source revision: | Retrieved: 2026-09-05. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
EMBLAVEO: selected primary-label renal guidance and limits
Source retrieved 2026-11-07 - confirm current applicability
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
Source scope / renal recommendation differences
EMBLAVEO: source applicability and renal evidence limits
The <=50 boundary and the loading-to-maintenance transition are retained from the detailed dosing tables; no dose is extrapolated to CRRT.
How to use this: Reassess changing CrCl; retain metronidazole for cIAI.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
EMBLAVEO (aztreonam and avibactam) for injection
Adults; IV fixed combination; doses below are TOTAL combination grams.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
U.S. IV combination product for adults with complicated intra-abdominal infection and limited alternatives, used with metronidazole. Not single-agent aztreonam or ceftazidime/avibactam.
aztreonam-avibactam-emblaveo:scope · Source section: Selected U.S. label: product title, route, dosage form and indicationRenal section finder
Maintenance starts at the next dosing interval after the single load; intervals run from infusion start to infusion start. Give after HD on dialysis days and monitor changing renal function closely. The labeled course is 5-14 days with concurrent metronidazole. Approval rests on limited clinical safety/efficacy data.
DailyMed / product prescribing information · Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.
Renal method: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam) Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Hemodialysis: administer after the session; no CRRT regimen established here.
Dialysis evidence: A regimen is reported in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Sections 2.1 and 2.2, Tables 1 and 2
Limits that apply to these rows
Read the complete source-specific limitations above and below this table. No patient dose is calculated.
Source-specific renal instructions
CrCl (mL/min)
Loading total
Maintenance total
Interval
>50
2.67 g
2 g
Every 6 hours
>30 to <=50
2.67 g
1 g
Every 6 hours
>15 to <=30
1.8 g
0.9 g
Every 8 hours
<=15, including HD
1.33 g
0.9 g
Every 12 hours
Read the retained text before reformatting
All doses infuse over 3 hours. Give one loading dose, then maintenance at the next interval; intervals run start-to-start. The table uses total combination dose, not aztreonam alone. Administer after hemodialysis on dialysis days. Follow changing CrCl closely; concurrent metronidazole is required for the labeled cIAI regimen.
RDM72-aztreonam-avibactam-emblaveo-label-1 · Source locator: Sections 2.1 and 2.2, Tables 1 and 2
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
GlobalRPh RX List / label mirror · Adult IV EMBLAVEO for labeled complicated intra-abdominal infection with concurrent metronidazole; not aztreonam alone.
Renal method: Cockcroft-Gault CrCl, mL/min; total combination grams (3:1 aztreonam:avibactam) Source date: Revision date not established in reviewed mirror passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding
Hemodialysis: administer after the session; no CRRT regimen established here.
Dialysis evidence: A regimen is reported in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Sections 2.1 and 2.2, Tables 1 and 2
The RX dosing section supplies CrCl-based loading and maintenance doses with three-hour infusions and post-hemodialysis timing. It uses Cockcroft-Gault and total combination dose; the mirror is not an independent regimen.
RDM72-aztreonam-avibactam-emblaveo-rx-1 · Source locator: Sections 2.1 and 2.2, Tables 1 and 2
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
